Hidradenitis Suppurativa (HS) is getting increased attention from dermatologists due to its frequent misdiagnosis and ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Fewer than half of respondents (46.9%) had a dermatologist as their primary ... in a large cohort with hidradenitis suppurativa. In Patients with HS, a Closer Look at Stigmatization and Perceived ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Christopher J. Sayed, MD, reports on how the 2025 American Academy of Dermatology Annual Meeting was an exciting event for hidradenitis suppurativa (HS), with increasing buzz and interest in the ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.